Ovi F (50Mg) 20 Tablets
Ovi-F 50mg tablets contain clomiphene citrate, an oral ovulation stimulant used under specialist supervision for selected women with documented ovulatory dysfunction. Treatment is given in short cycles and requires pregnancy exclusion, pelvic assessment, and monitoring for ovarian enlargement, visual symptoms, and multiple pregnancy.
₨ 412
Overview
Ovi-F 50mg Tablets contain clomiphene citrate USP 50 mg per tablet. Clomiphene is an oral ovulation stimulant used for carefully selected women who have documented ovulatory dysfunction and wish to become pregnant. It is not a general fertility supplement and should not be started until pregnancy, ovarian enlargement or cysts, unexplained uterine bleeding, liver dysfunction, and other causes of infertility have been assessed.
The product is manufactured by Martin Dow Marker Ltd. The supplied product image shows a box of 10 tablets, while the listing title states 20 tablets. Confirm the actual pack configuration shown on the invoice and medicine pack before dispensing or use.
Benefits
- May induce ovulation in women with irregular or absent ovulation
- Supports ovarian follicle maturation through increased pituitary gonadotropin activity
- Provides an oral treatment option for selected ovulatory disorders
Key Features
- Clomiphene citrate USP 50 mg per tablet
- Oral ovulation-stimulating medicine
- Short, clinician-directed treatment courses
- Requires assessment and monitoring between cycles
- Manufactured by Martin Dow Marker Ltd.
Dosage and How to Use
- How to use: Take exactly as prescribed in a short treatment course. Swallow the prescribed tablet dose orally with water. Do not change the dose, start day, or number of treatment days without the prescriber's approval.
- Administration: Oral administration. Use only according to the clinician-directed fertility treatment schedule.
- Recommended dose: Only under specialist supervision: the product leaflet recommends an initial dose of 50 mg once daily for 5 days. If ovulation does not occur, a second course of 100 mg once daily for 5 days may be considered after reassessment and exclusion of pregnancy.
- Adult dose: Initial course: 50 mg once daily for 5 days. If ovulation does not occur, a clinician may prescribe 100 mg once daily for 5 days after reassessment. Doses above 100 mg daily or courses longer than 5 days are not recommended in the product leaflet.
- When to take: The treatment start day is selected by the prescriber according to the menstrual or induced-bleeding pattern. The product leaflet describes starting around the fifth day of the cycle when bleeding has occurred.
- Maximum daily dose: 100 mg per day, with a treatment course not exceeding 5 days, according to the product leaflet.
- Overdose: Seek urgent medical care or contact a poison-control service. Reported overdose features may include nausea, vomiting, hot flushes, visual blurring or spots, and ovarian enlargement with pelvic or abdominal pain. Treatment is supportive; take the medicine pack with you.
Specifications
| Brand | Martin Dow |
|---|---|
| Manufacturer | Martin Dow Marker Ltd. |
| Country of Origin | Pakistan |
| Drug class | Ovulation stimulant; selective estrogen receptor modulator (SERM) |
| Therapeutic category | Female fertility medicine and ovulation stimulant |
| Age group | Adults |
| Suitable for | Adult women with demonstrated ovulatory dysfunction who have been appropriately evaluated | Patients who are not pregnant, have normal liver function, and do not have unexplained uterine bleeding or disqualifying ovarian cysts |
Side Effects
Common side effects
- Ovarian enlargement
- Hot flushes
- Abdominal or pelvic discomfort
- Bloating
- Nausea or vomiting
- Breast discomfort
- Headache
- Dizziness
- Spotting or heavier menstrual bleeding
- Visual blurring, spots, or flashes
Serious side effects (seek medical help)
- Ovarian hyperstimulation syndrome
- Persistent or severe visual disturbance
- Severe pelvic or abdominal pain with ovarian enlargement
- Thromboembolic events such as leg swelling, chest pain, or shortness of breath
- Jaundice or other signs of liver injury
- Severe allergic reaction
- Ectopic pregnancy
Allergic reaction
Do not use if allergic to clomiphene citrate or any ingredient in the tablet. Seek urgent care for facial swelling, breathing difficulty, widespread rash, or other signs of a severe allergic reaction.
Safety and Precautions
- Ovarian hyperstimulation syndrome may develop and can become serious
- Visual symptoms may be prolonged and may rarely persist after treatment
- Treatment increases the chance of multiple pregnancy
- Ectopic pregnancy has been reported after conception with clomiphene therapy
- Pregnancy must be excluded before each treatment course
- Pelvic evaluation is required before the first and subsequent courses
- Use caution in patients with polycystic ovary syndrome because of increased sensitivity
- Use caution with uterine fibroids because enlargement may occur
- Assess unexplained uterine bleeding before treatment
- Investigate thyroid, adrenal, pituitary, and other fertility factors before use
When not to use
Pregnancy | Known hypersensitivity to clomiphene citrate or any tablet ingredient | Liver disease or a history of liver dysfunction | Hormone-dependent tumours | Unexplained abnormal uterine bleeding | Ovarian cysts or enlargement not caused by polycystic ovary syndrome | Uncontrolled thyroid or adrenal dysfunction | Organic intracranial lesions such as a pituitary tumour
Special populations
- Pregnancy: Contraindicated during pregnancy. Pregnancy must be excluded before treatment and between courses. Stop treatment and contact the prescriber if pregnancy is suspected or confirmed.
- Breastfeeding: It is not known whether clomiphene passes into human milk. It may reduce lactation. Obtain specialist advice before use while breastfeeding.
- Fertility: This medicine is used to induce ovulation but does not guarantee pregnancy. It increases the chance of multiple pregnancy and has been associated with ectopic pregnancy; these risks should be discussed before treatment.
- Liver: Contraindicated in patients with liver disease or a history of liver dysfunction. Stop treatment and seek medical assessment for jaundice, dark urine, or other signs of liver injury.
- Driving: Do not drive or operate machinery if blurred vision, spots, flashes, or other visual symptoms occur. Visual disturbances may rarely be prolonged.
Interactions
Drugs:
- The product leaflet states that drug interactions have not been documented. Patients should still tell the prescriber about all prescription medicines, non-prescription medicines, vitamins, and supplements before treatment.
Conditions:
- Liver disease
- Ovarian cysts or ovarian enlargement
- Polycystic ovary syndrome
- Unexplained uterine bleeding
- Hormone-dependent tumours
- Uncontrolled thyroid or adrenal dysfunction
- Pituitary or other organic intracranial lesions
- Uterine fibroids
- History or risk of ovarian hyperstimulation
Storage and Disposal
- Store in the original packaging below 30°C. Protect from light, heat, and moisture.
- Store below 30°C.
- Keep out of the reach and sight of children.
- Return unused or expired tablets to a pharmacy or follow local medicine-disposal guidance. Do not share the medicine or dispose of it where children or animals can reach it.
Disclaimer
This product information is for identification and safe-use education only and is not a substitute for medical advice, diagnosis, fertility assessment, or prescribing. Use Ovi-F only as directed by a qualified healthcare professional, read the enclosed leaflet, and obtain appropriate pregnancy exclusion and monitoring. Seek urgent care for severe symptoms or suspected overdose.
| Strength | (50Mg) 20 Tablets, Tablets 10s |
|---|---|
| Introduction Of Product | Ovi-F 50mg Tablets contain clomiphene citrate USP 50 mg per tablet. They are used to stimulate ovulation in carefully selected adult women with documented ovulatory dysfunction who wish to become pregnant. |
| Source | D.Watson, Health Wire |
| Key Features | Clomiphene citrate USP 50 mg per tablet, Oral ovulation-stimulating medicine, Short, clinician-directed treatment courses, Requires assessment and monitoring between cycles, Manufactured by Martin Dow Marker Ltd. |
| Key Benefits | May induce ovulation in women with irregular or absent ovulation, Supports ovarian follicle maturation through increased pituitary gonadotropin activity, Provides an oral treatment option for selected ovulatory disorders |
| Primary Uses | Induction of ovulation in women with documented ovulatory dysfunction, Management of selected anovulatory infertility under specialist supervision |
| Drug Class | Ovulation stimulant; selective estrogen receptor modulator (SERM) |
| Indications | Ovulatory dysfunction in women who desire pregnancy, Selected cases associated with polycystic ovary syndrome, Selected cases of secondary amenorrhea after appropriate evaluation |
| Used For | Stimulating ovulation, Treating selected forms of female infertility caused by absent or irregular ovulation |
| Suitable For | Adult women with demonstrated ovulatory dysfunction who have been appropriately evaluated, Patients who are not pregnant, have normal liver function, and do not have unexplained uterine bleeding or disqualifying ovarian cysts |
| Who Itu2019s For | Adult women with documented ovulatory dysfunction who wish to become pregnant and have been selected for treatment by a qualified healthcare professional. |
| How It Works | Clomiphene alters estrogen feedback at the hypothalamus, increasing pituitary release of follicle-stimulating hormone and luteinizing hormone. In responsive patients, this promotes ovarian follicle maturation and may trigger ovulation. |
| Therapeutic Category | Female fertility medicine and ovulation stimulant |
| Manufacturer | Martin Dow Marker Ltd. |
| Country of Origin | Pakistan |
| Recommended Dose | Only under specialist supervision: the product leaflet recommends an initial dose of 50 mg once daily for 5 days. If ovulation does not occur, a second course of 100 mg once daily for 5 days may be considered after reassessment and exclusion of pregnancy. |
| How to Use | Take exactly as prescribed in a short treatment course. Swallow the prescribed tablet dose orally with water. Do not change the dose, start day, or number of treatment days without the prescriber's approval. |
| When to Take | The treatment start day is selected by the prescriber according to the menstrual or induced-bleeding pattern. The product leaflet describes starting around the fifth day of the cycle when bleeding has occurred. |
| Maximum Daily Dose | 100 mg per day, with a treatment course not exceeding 5 days, according to the product leaflet. |
| Age Group | Adults |
| Adult Dose | Initial course: 50 mg once daily for 5 days. If ovulation does not occur, a clinician may prescribe 100 mg once daily for 5 days after reassessment. Doses above 100 mg daily or courses longer than 5 days are not recommended in the product leaflet. |
| Overdose Instructions | Seek urgent medical care or contact a poison-control service. Reported overdose features may include nausea, vomiting, hot flushes, visual blurring or spots, and ovarian enlargement with pelvic or abdominal pain. Treatment is supportive; take the medicine pack with you. |
| Administration Instructions | Oral administration. Use only according to the clinician-directed fertility treatment schedule. |
| Warnings | Ovarian hyperstimulation syndrome may develop and can become serious, Visual symptoms may be prolonged and may rarely persist after treatment, Treatment increases the chance of multiple pregnancy, Ectopic pregnancy has been reported after conception with clomiphene therapy, Pregnancy must be excluded before each treatment course |
| Precautions | Pelvic evaluation is required before the first and subsequent courses, Use caution in patients with polycystic ovary syndrome because of increased sensitivity, Use caution with uterine fibroids because enlargement may occur, Assess unexplained uterine bleeding before treatment, Investigate thyroid, adrenal, pituitary, and other fertility factors before use |
| Contraindications | Pregnancy, Known hypersensitivity to clomiphene citrate or any tablet ingredient, Liver disease or a history of liver dysfunction, Hormone-dependent tumours, Unexplained abnormal uterine bleeding, Ovarian cysts or enlargement not caused by polycystic ovary syndrome, Uncontrolled thyroid or adrenal dysfunction, Organic intracranial lesions such as a pituitary tumour |
| When Not to Use | Do not use during pregnancy or in patients with clomiphene allergy, liver disease or prior liver dysfunction, hormone-dependent tumours, unexplained uterine bleeding, non-PCOS ovarian cysts or enlargement, uncontrolled thyroid or adrenal dysfunction, or an organic intracranial lesion. |
| Allergy Warning | Do not use if allergic to clomiphene citrate or any ingredient in the tablet. Seek urgent care for facial swelling, breathing difficulty, widespread rash, or other signs of a severe allergic reaction. |
| Common Side Effects | Ovarian enlargement, Hot flushes, Abdominal or pelvic discomfort, Bloating, Nausea or vomiting, Breast discomfort, Headache, Dizziness, Spotting or heavier menstrual bleeding, Visual blurring, spots, or flashes |
| Serious Side Effects | Ovarian hyperstimulation syndrome, Persistent or severe visual disturbance, Severe pelvic or abdominal pain with ovarian enlargement, Thromboembolic events such as leg swelling, chest pain, or shortness of breath, Jaundice or other signs of liver injury, Severe allergic reaction, Ectopic pregnancy |
| Pregnancy Warning | Contraindicated during pregnancy. Pregnancy must be excluded before treatment and between courses. Stop treatment and contact the prescriber if pregnancy is suspected or confirmed. |
| Breastfeeding Warning | It is not known whether clomiphene passes into human milk. It may reduce lactation. Obtain specialist advice before use while breastfeeding. |
| Fertility Warning | This medicine is used to induce ovulation but does not guarantee pregnancy. It increases the chance of multiple pregnancy and has been associated with ectopic pregnancy; these risks should be discussed before treatment. |
| Liver Warning | Contraindicated in patients with liver disease or a history of liver dysfunction. Stop treatment and seek medical assessment for jaundice, dark urine, or other signs of liver injury. |
| Driving or Machine Use Warning | Do not drive or operate machinery if blurred vision, spots, flashes, or other visual symptoms occur. Visual disturbances may rarely be prolonged. |
| Drug Interactions | The product leaflet states that drug interactions have not been documented. Patients should still tell the prescriber about all prescription medicines, non-prescription medicines, vitamins, and supplements before treatment. |
| Disease Interactions | Liver disease, Ovarian cysts or ovarian enlargement, Polycystic ovary syndrome, Unexplained uterine bleeding, Hormone-dependent tumours, Uncontrolled thyroid or adrenal dysfunction, Pituitary or other organic intracranial lesions, Uterine fibroids, History or risk of ovarian hyperstimulation |
| Storage Instructions | Store in the original packaging below 30°C. Protect from light, heat, and moisture. |
| Disposal Instructions | Return unused or expired tablets to a pharmacy or follow local medicine-disposal guidance. Do not share the medicine or dispose of it where children or animals can reach it. |
| Keep Away From Children | Keep out of the reach and sight of children. |
| Temperature Requirement | Store below 30°C. |
| Disclaimer | This product information is for identification and safe-use education only and is not a substitute for medical advice, diagnosis, fertility assessment, or prescribing. Use Ovi-F only as directed by a qualified healthcare professional, read the enclosed leaflet, and obtain appropriate pregnancy exclusion and monitoring. Seek urgent care for severe symptoms or suspected overdose. |
All In One Medicine policy reference: Shipping Policy | Return Policy | Refund Policy
This product may be fulfilled through the source shown below. Source fees, delivery coverage, payment limits, return windows, and refund routes can be stricter than ordinary ecommerce because medicines, prescriptions, cold-chain items, baby products, hygiene goods, and opened products have safety limits.
This product may be fulfilled through more than one source. The applicable delivery, payment, return, and refund rule depends on which source ships the item. Source sections shown below: D.Watson, Health Wire.
Shipping & Delivery - D.Watson
Delivery and support
- D.Watson is a pharmacy and super store chain with a strong Islamabad and Rawalpindi presence and online ordering through dwatson.pk.
- D.Watson does not publish a separate shipping policy page; delivery timing and service area are confirmed by its support team after order placement.
- Prescription medicines are dispatched only after prescription review.
- For delivery and order questions, use 0332-8447777, 051-8447077, or [email protected].
Refund and return restrictions
- D.Watson states that debit or credit card refunds are not offered under its standard policy.
- D.Watson states that JazzCash mobile wallet refunds are not offered under its standard policy.
- Exceptional refunds may be considered case by case and require support approval through 0332-8447777.
- No explicit public return window was found. Opened, used, or temperature-sensitive medicines should be treated as restricted unless support approves an exception.
Shipping & Delivery - Health Wire
Delivery, return, and refund handling
- Healthwire routes medicine orders to the dispensing partner pharmacy that accepts the order.
- Services are restricted to selected territories within Pakistan.
- Prescription medicine ordering is restricted to customers aged 18 or older.
- Delivery time, courier choice, delivery fee, and serviceability are set by the dispensing partner pharmacy and confirmed at order time.
- Healthwire does not publish one unified shipping or return policy for all pharmacy orders.
- The return and refund terms for a medicine order are the actual dispensing partner pharmacy terms.
- Standard pharmacy restrictions still apply to opened, used, prescription, hygiene-sensitive, and temperature-sensitive products.
Reviews
There are no reviews yet.